MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
PerkinElmer Interest Expense 2011-2026 | PKI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -38 M | -3.36 M | -4.72 M | - | 63.6 M | 67 M | 43.9 M | 38 M | - | 36.3 M | 49.9 M | 45.8 M | 15.9 M | 16 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67 M | -38 M | 27.5 M |
Quarterly Interest Expense PerkinElmer
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 24.7 M | 24.4 M | - | 25.5 M | 26 M | 22.7 M | - | 25.9 M | 27.1 M | 28.4 M | - | 43.5 M | 16.8 M | 14.1 M | - | 12.1 M | 11.6 M | 13.7 M | - | 16.1 M | 17.2 M | 15.8 M | - | 16.7 M | 16.4 M | 17.6 M | - | 11 M | 10.7 M | 10.9 M | - | 11 M | 9.94 M | 9.84 M | - | 9.87 M | 9.3 M | 9.39 M | - | 8.91 M | 9.08 M | 9.22 M | - | 11.7 M | 11.9 M | 11.7 M | - | 11.4 M | 11.3 M | 11.4 M | - | 4.45 M | 4.21 M | 3.92 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.5 M | 3.92 M | 15.1 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
5.33 M | $ 88.57 | -4.22 % | $ 4.14 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
106 K | $ 5.32 | -7.68 % | $ 7.08 M | USA |
 |
Castle Biosciences
CSTL
|
144 K | $ 21.2 | -1.85 % | $ 615 M | USA |
 |
Fulgent Genetics
FLGT
|
153 K | $ 19.02 | -2.46 % | $ 585 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-595 K | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 126.28 | -5.1 % | $ 15.8 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.65 | -7.82 % | $ 7.3 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 22.06 | -4.58 % | $ 1.18 B | USA |
 |
Illumina
ILMN
|
340 M | $ 161.86 | -3.69 % | $ 25.1 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 148.91 | -2.55 % | $ 11.7 B |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 101.99 | -0.81 % | $ 6.88 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
17.6 K | - | - | $ 7.1 B |  Australia |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 10.82 | -4.33 % | $ 1.39 B | USA |
 |
Natera
NTRA
|
4.07 M | $ 215.8 | -2.84 % | $ 29.5 B | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 182.78 | -1.63 % | $ 9.06 B | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.4 | -13.85 % | $ 420 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 455.2 | -0.76 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 154.6 | -2.19 % | $ 23.8 B |  Schweiz |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.63 | -1.39 % | $ 429 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 19.56 | -0.96 % | $ 438 M | USA |
 |
Personalis
PSNL
|
205 K | $ 10.54 | -12.93 % | $ 941 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.17 | 0.67 % | $ 24.8 B |  Niderland |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.63 | -5.49 % | $ 277 M | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
2.58 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.15 | 0.23 % | $ 4.94 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 266.2 | 1.95 % | $ 22.1 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 68.92 | -6.78 % | $ 4.12 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 474.12 | -1.65 % | $ 179 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.67 | -1.96 % | $ 241 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Waters Corporation
WAT
|
14.3 M | $ 367.04 | -2.49 % | $ 21.9 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 8.99 | -1.48 % | $ 1.95 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 201.12 | 2.53 % | $ 22.3 B | USA |